Residual disease is the main, but not the only factor impacting satisfaction in psoriatic patients undergoing biological therapies

Despite advancements in psoriasis treatment, a gap remains in aligning patient satisfaction with clinical outcomes. Our study aimed to evaluate which clinical and psychological factors may impact treatment satisfaction in psoriatic patients undergoing long-term biological therapies. We performed an...

Full description

Saved in:
Bibliographic Details
Published in:International journal of dermatology 2024-10
Main Authors: Caldarola, Giacomo, De Luca, Eleonora, Falco, Gennaro Marco, Di Nardo, Lucia, Bocchino, Enrico, D'Agostino, Magda, Peris, Ketty, De Simone, Clara
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c210t-46c16687930db31d9c731a13202e790ebc6028de8bd823e28f37117e3c880a723
container_end_page
container_issue
container_start_page
container_title International journal of dermatology
container_volume
creator Caldarola, Giacomo
De Luca, Eleonora
Falco, Gennaro Marco
Di Nardo, Lucia
Bocchino, Enrico
D'Agostino, Magda
Peris, Ketty
De Simone, Clara
description Despite advancements in psoriasis treatment, a gap remains in aligning patient satisfaction with clinical outcomes. Our study aimed to evaluate which clinical and psychological factors may impact treatment satisfaction in psoriatic patients undergoing long-term biological therapies. We performed an observational, cross-sectional, single-center study involving adult patients with moderate-to-severe psoriasis treated with biologics for at least 12 months. We collected sociodemographic characteristics and data on the course of the psoriasis. We also assessed the absolute (residual) Psoriasis Area and Severity Index (PASI), the site of the residual disease, and the severity of pruritus through the Visual Analogue Scale (VAS). Satisfaction was evaluated using the Treatment Satisfaction Questionnaire for Medication (TSQMv.II). The Type D Personality Scale (DS14 questionnaire and Patient Health Questionnaire-9 assessed the psychological profile. Overall, 146 patients were included, and 82.1% were globally satisfied (global satisfaction TSQM score >75). Linear regression analysis showed a negative correlation between global satisfaction scoring and residual PASI. The multivariable analysis found a higher VAS-pruritus score (OR = 1.20, 95% CI = 1.01-1.44; P = 0.043) and not reaching a residual PASI 
doi_str_mv 10.1111/ijd.17509
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3114152382</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3114152382</sourcerecordid><originalsourceid>FETCH-LOGICAL-c210t-46c16687930db31d9c731a13202e790ebc6028de8bd823e28f37117e3c880a723</originalsourceid><addsrcrecordid>eNo9kE9rGzEQxUVJqJ20h3yBoGMKsauRvCvtsZi2CRgCpT0vWmnsyuxKW83uIdd88sr5p4M0evx4w3uMXYFYQzlfw9GvQVei-cCWoOpqtamVPGNLIQBWjaiaBbsgOpavkrD5yBaqUbrSjVmyp19Iwc-25z4QWkIeiE9_kQ82xFvezROPaXpWUuwf-d66KWUehrEMIR442SnQSQ0p8hD5SCmHojk-lhvjRHyOHvMhnegupD4dgiv7imW2Y0D6xM73tif8_Ppesj8_vv_e3q12Dz_vt992KydBTCWTg7o2ulHCdwp847QCWxIJiboR2LlaSOPRdN5IhdLslQbQqJwxwmqpLtnNi--Y078ZaWqHQA773kZMM7UKYAOVVOaEfnlBXU5EGfftmMNg82MLoj1V3pbK2-fKC3v9ajt3A_p38q1j9R-CEn3C</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3114152382</pqid></control><display><type>article</type><title>Residual disease is the main, but not the only factor impacting satisfaction in psoriatic patients undergoing biological therapies</title><source>Wiley</source><creator>Caldarola, Giacomo ; De Luca, Eleonora ; Falco, Gennaro Marco ; Di Nardo, Lucia ; Bocchino, Enrico ; D'Agostino, Magda ; Peris, Ketty ; De Simone, Clara</creator><creatorcontrib>Caldarola, Giacomo ; De Luca, Eleonora ; Falco, Gennaro Marco ; Di Nardo, Lucia ; Bocchino, Enrico ; D'Agostino, Magda ; Peris, Ketty ; De Simone, Clara</creatorcontrib><description>Despite advancements in psoriasis treatment, a gap remains in aligning patient satisfaction with clinical outcomes. Our study aimed to evaluate which clinical and psychological factors may impact treatment satisfaction in psoriatic patients undergoing long-term biological therapies. We performed an observational, cross-sectional, single-center study involving adult patients with moderate-to-severe psoriasis treated with biologics for at least 12 months. We collected sociodemographic characteristics and data on the course of the psoriasis. We also assessed the absolute (residual) Psoriasis Area and Severity Index (PASI), the site of the residual disease, and the severity of pruritus through the Visual Analogue Scale (VAS). Satisfaction was evaluated using the Treatment Satisfaction Questionnaire for Medication (TSQMv.II). The Type D Personality Scale (DS14 questionnaire and Patient Health Questionnaire-9 assessed the psychological profile. Overall, 146 patients were included, and 82.1% were globally satisfied (global satisfaction TSQM score &gt;75). Linear regression analysis showed a negative correlation between global satisfaction scoring and residual PASI. The multivariable analysis found a higher VAS-pruritus score (OR = 1.20, 95% CI = 1.01-1.44; P = 0.043) and not reaching a residual PASI &lt; 2 (OR = 0.30, 95% CI = 0.09-0.94, P = 0.039) as the strongest predictors of global unsatisfied patients (TSQM &lt; 75%). Other factors unrelated to residual disease, such as gender, class of biologic agent, and type D personality, have also been found to impact patient satisfaction. Our study's findings underscore the complexity of patient satisfaction in psoriasis management and highlight the multifactorial nature of treatment success beyond traditional clinical measures.</description><identifier>ISSN: 0011-9059</identifier><identifier>ISSN: 1365-4632</identifier><identifier>EISSN: 1365-4632</identifier><identifier>DOI: 10.1111/ijd.17509</identifier><identifier>PMID: 39375798</identifier><language>eng</language><publisher>England</publisher><ispartof>International journal of dermatology, 2024-10</ispartof><rights>2024 The Author(s). International Journal of Dermatology published by Wiley Periodicals LLC on behalf of the International Society of Dermatology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c210t-46c16687930db31d9c731a13202e790ebc6028de8bd823e28f37117e3c880a723</cites><orcidid>0000-0002-8837-9232 ; 0000-0001-9208-8887 ; 0000-0003-3893-2869 ; 0009-0001-1219-9008</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39375798$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Caldarola, Giacomo</creatorcontrib><creatorcontrib>De Luca, Eleonora</creatorcontrib><creatorcontrib>Falco, Gennaro Marco</creatorcontrib><creatorcontrib>Di Nardo, Lucia</creatorcontrib><creatorcontrib>Bocchino, Enrico</creatorcontrib><creatorcontrib>D'Agostino, Magda</creatorcontrib><creatorcontrib>Peris, Ketty</creatorcontrib><creatorcontrib>De Simone, Clara</creatorcontrib><title>Residual disease is the main, but not the only factor impacting satisfaction in psoriatic patients undergoing biological therapies</title><title>International journal of dermatology</title><addtitle>Int J Dermatol</addtitle><description>Despite advancements in psoriasis treatment, a gap remains in aligning patient satisfaction with clinical outcomes. Our study aimed to evaluate which clinical and psychological factors may impact treatment satisfaction in psoriatic patients undergoing long-term biological therapies. We performed an observational, cross-sectional, single-center study involving adult patients with moderate-to-severe psoriasis treated with biologics for at least 12 months. We collected sociodemographic characteristics and data on the course of the psoriasis. We also assessed the absolute (residual) Psoriasis Area and Severity Index (PASI), the site of the residual disease, and the severity of pruritus through the Visual Analogue Scale (VAS). Satisfaction was evaluated using the Treatment Satisfaction Questionnaire for Medication (TSQMv.II). The Type D Personality Scale (DS14 questionnaire and Patient Health Questionnaire-9 assessed the psychological profile. Overall, 146 patients were included, and 82.1% were globally satisfied (global satisfaction TSQM score &gt;75). Linear regression analysis showed a negative correlation between global satisfaction scoring and residual PASI. The multivariable analysis found a higher VAS-pruritus score (OR = 1.20, 95% CI = 1.01-1.44; P = 0.043) and not reaching a residual PASI &lt; 2 (OR = 0.30, 95% CI = 0.09-0.94, P = 0.039) as the strongest predictors of global unsatisfied patients (TSQM &lt; 75%). Other factors unrelated to residual disease, such as gender, class of biologic agent, and type D personality, have also been found to impact patient satisfaction. Our study's findings underscore the complexity of patient satisfaction in psoriasis management and highlight the multifactorial nature of treatment success beyond traditional clinical measures.</description><issn>0011-9059</issn><issn>1365-4632</issn><issn>1365-4632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kE9rGzEQxUVJqJ20h3yBoGMKsauRvCvtsZi2CRgCpT0vWmnsyuxKW83uIdd88sr5p4M0evx4w3uMXYFYQzlfw9GvQVei-cCWoOpqtamVPGNLIQBWjaiaBbsgOpavkrD5yBaqUbrSjVmyp19Iwc-25z4QWkIeiE9_kQ82xFvezROPaXpWUuwf-d66KWUehrEMIR442SnQSQ0p8hD5SCmHojk-lhvjRHyOHvMhnegupD4dgiv7imW2Y0D6xM73tif8_Ppesj8_vv_e3q12Dz_vt992KydBTCWTg7o2ulHCdwp847QCWxIJiboR2LlaSOPRdN5IhdLslQbQqJwxwmqpLtnNi--Y078ZaWqHQA773kZMM7UKYAOVVOaEfnlBXU5EGfftmMNg82MLoj1V3pbK2-fKC3v9ajt3A_p38q1j9R-CEn3C</recordid><startdate>20241007</startdate><enddate>20241007</enddate><creator>Caldarola, Giacomo</creator><creator>De Luca, Eleonora</creator><creator>Falco, Gennaro Marco</creator><creator>Di Nardo, Lucia</creator><creator>Bocchino, Enrico</creator><creator>D'Agostino, Magda</creator><creator>Peris, Ketty</creator><creator>De Simone, Clara</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8837-9232</orcidid><orcidid>https://orcid.org/0000-0001-9208-8887</orcidid><orcidid>https://orcid.org/0000-0003-3893-2869</orcidid><orcidid>https://orcid.org/0009-0001-1219-9008</orcidid></search><sort><creationdate>20241007</creationdate><title>Residual disease is the main, but not the only factor impacting satisfaction in psoriatic patients undergoing biological therapies</title><author>Caldarola, Giacomo ; De Luca, Eleonora ; Falco, Gennaro Marco ; Di Nardo, Lucia ; Bocchino, Enrico ; D'Agostino, Magda ; Peris, Ketty ; De Simone, Clara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c210t-46c16687930db31d9c731a13202e790ebc6028de8bd823e28f37117e3c880a723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Caldarola, Giacomo</creatorcontrib><creatorcontrib>De Luca, Eleonora</creatorcontrib><creatorcontrib>Falco, Gennaro Marco</creatorcontrib><creatorcontrib>Di Nardo, Lucia</creatorcontrib><creatorcontrib>Bocchino, Enrico</creatorcontrib><creatorcontrib>D'Agostino, Magda</creatorcontrib><creatorcontrib>Peris, Ketty</creatorcontrib><creatorcontrib>De Simone, Clara</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Caldarola, Giacomo</au><au>De Luca, Eleonora</au><au>Falco, Gennaro Marco</au><au>Di Nardo, Lucia</au><au>Bocchino, Enrico</au><au>D'Agostino, Magda</au><au>Peris, Ketty</au><au>De Simone, Clara</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Residual disease is the main, but not the only factor impacting satisfaction in psoriatic patients undergoing biological therapies</atitle><jtitle>International journal of dermatology</jtitle><addtitle>Int J Dermatol</addtitle><date>2024-10-07</date><risdate>2024</risdate><issn>0011-9059</issn><issn>1365-4632</issn><eissn>1365-4632</eissn><abstract>Despite advancements in psoriasis treatment, a gap remains in aligning patient satisfaction with clinical outcomes. Our study aimed to evaluate which clinical and psychological factors may impact treatment satisfaction in psoriatic patients undergoing long-term biological therapies. We performed an observational, cross-sectional, single-center study involving adult patients with moderate-to-severe psoriasis treated with biologics for at least 12 months. We collected sociodemographic characteristics and data on the course of the psoriasis. We also assessed the absolute (residual) Psoriasis Area and Severity Index (PASI), the site of the residual disease, and the severity of pruritus through the Visual Analogue Scale (VAS). Satisfaction was evaluated using the Treatment Satisfaction Questionnaire for Medication (TSQMv.II). The Type D Personality Scale (DS14 questionnaire and Patient Health Questionnaire-9 assessed the psychological profile. Overall, 146 patients were included, and 82.1% were globally satisfied (global satisfaction TSQM score &gt;75). Linear regression analysis showed a negative correlation between global satisfaction scoring and residual PASI. The multivariable analysis found a higher VAS-pruritus score (OR = 1.20, 95% CI = 1.01-1.44; P = 0.043) and not reaching a residual PASI &lt; 2 (OR = 0.30, 95% CI = 0.09-0.94, P = 0.039) as the strongest predictors of global unsatisfied patients (TSQM &lt; 75%). Other factors unrelated to residual disease, such as gender, class of biologic agent, and type D personality, have also been found to impact patient satisfaction. Our study's findings underscore the complexity of patient satisfaction in psoriasis management and highlight the multifactorial nature of treatment success beyond traditional clinical measures.</abstract><cop>England</cop><pmid>39375798</pmid><doi>10.1111/ijd.17509</doi><orcidid>https://orcid.org/0000-0002-8837-9232</orcidid><orcidid>https://orcid.org/0000-0001-9208-8887</orcidid><orcidid>https://orcid.org/0000-0003-3893-2869</orcidid><orcidid>https://orcid.org/0009-0001-1219-9008</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0011-9059
ispartof International journal of dermatology, 2024-10
issn 0011-9059
1365-4632
1365-4632
language eng
recordid cdi_proquest_miscellaneous_3114152382
source Wiley
title Residual disease is the main, but not the only factor impacting satisfaction in psoriatic patients undergoing biological therapies
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T05%3A20%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Residual%20disease%20is%20the%20main,%20but%20not%20the%20only%20factor%20impacting%20satisfaction%20in%20psoriatic%20patients%20undergoing%20biological%20therapies&rft.jtitle=International%20journal%20of%20dermatology&rft.au=Caldarola,%20Giacomo&rft.date=2024-10-07&rft.issn=0011-9059&rft.eissn=1365-4632&rft_id=info:doi/10.1111/ijd.17509&rft_dat=%3Cproquest_cross%3E3114152382%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c210t-46c16687930db31d9c731a13202e790ebc6028de8bd823e28f37117e3c880a723%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3114152382&rft_id=info:pmid/39375798&rfr_iscdi=true